Search
  • Site Search
  • News
  • Product
  • Zhejiang Medical Technology Development Co., Ltd.

    2020 year
    12
    30 day
    Winhealth Pharma Becomes First Cross-border E-commerce Partner of PrecisionBiotics®

    Recently, Hongkong Winhealth Pharma Group Co., Ltd. has become the first cross-border e-commerce partner of PrecisionBiotics®, a well-known Irish probiotics brand. The first PrecisionBiotics® cross-border e-commerce flagship store operated by Hongkong Winhealth Pharma Group Co., Ltd. is officially launched on Tmall Global.

    Winhealth Pharma Becomes First Cross-border E-commerce Partner of Well-known Irish Probiotics Brand

    PrecisionBiotics®, an excellent probiotics brand originating from Ireland, is a precise and unique probiotics brand with distinctive ingenuity. With the concept of natural, precise and scientific research and development, it is committed to developing excellent and innovative probiotics strains in nature to help consumers solve their health problems. Since its inception in 2000, the brand has accumulated more than 20 years of R&D experience. It has rich experience in strain identification, gene expression, precise screening and other aspects, which has been highly recognized in the industry. It has achieved the isolation of multiple strains and its commercialized application in consumer and medical products. Since the brand development is always based on science, it provides high-quality solutions for intestinal health through precise screening, cultivation and formulation of strains.

     

    Winhealth Pharma Becomes First Cross-border E-commerce Partner of Well-known Irish Probiotics Brand Winhealth Pharma Becomes First Cross-border E-commerce Partner of Well-known Irish Probiotics Brand

     

    The two probiotics products marketed in China this time are Zenflore® and Alflorex®. Zenflore® contains bifidobacterium longum 1714-Serenitas®, a patented strain designed to relieve anxiety and promote sleep. In the hustle and bustle of city life, the problems that the post-80s, post-90s and even post-00s generations have to face are to better deal with various challenges in a fast-paced life, relieve the anxiety caused by stress, calmly deal with various emergencies in school, work and life, and start a new day in a more relaxed and energetic way. 1

     

    As from today, the first PrecisionBiotics® cross-border e-commerce flagship store operated by Hongkong Winhealth Pharma Group Co., Ltd. with sole agency right is officially launched on Tmall Global. After searching Alflorex® or Zenflore® on Taobao, Chinese consumers can purchase professional probiotics products originating from Ireland and enjoy the high quality of life as in Europe.

     

    The signing of the cross-border e-commerce cooperation marks the establishment of a long-term and stable strategic partnership between Hongkong Winhealth Pharma Group Co., Ltd. and Novozymes.

     

    In the future, both parties will continue to innovate in cooperation models and explore broader prospects for global cooperation. Meanwhile, both parties will continue to promote the sustained development of PrecisionBiotics® in China’s health field by virtue of their professional influence in the industry, and make a positive contribution to China’s health undertaking.

     

    Winhealth Pharma Becomes First Cross-border E-commerce Partner of Well-known Irish Probiotics Brand

    Winhealth Pharma Becomes First Cross-border E-commerce Partner of Well-known Irish Probiotics Brand Winhealth Pharma Becomes First Cross-border E-commerce Partner of Well-known Irish Probiotics Brand  

    In June 2020, Novozymes OneHealth acquired PrecisionBiotics (PBG), an Irish probiotics company, at a price of 80 million euros, further strengthening the technical advantages of both parties in the field of probiotics research and development.

     

    About Novozymes

    Novozymes is one of the largest Danish investment companies in China. It is an excellent company of industrial enzyme products and microbial products in the world, providing innovative solutions for the global market. In 2001, Novozymes was separated from Novo Nordisk, a Danish pharmaceutical company. By 2019, its global sales revenue had reached 14.7 billion yuan, with operations in 130 countries. Novozymes has 6000 employees who are engaged in R&D, production, sales and administration worldwide. Novozymes has been listed on the Copenhagen Stock Exchange in Denmark (stock symbol: NZYM B).

     

    Since entering China in 1997, Novozymes has set up the first R&D center for a foreign-funded biotechnology company in China. The R&D center is located in the Novozymes Headquarters of China Region in the Beijing Zhongguancun Science Park, with a modern laboratory covering an area of 5,000 square meters. Researchers apply a variety of advanced core technologies in traditional microbiology, modern biochemistry, molecular biology, bioinformatics and other fields, including expression cloning, recombinant technology, protein engineering and high-throughput screening.

     

    In 2019, Novozymes established OneHealth, a human health business brand. Backed by Novozymes’s powerful biotechnologies and outstanding R&D capabilities, Novozymes is committed to creating a new future of human health through bold experiment and innovation based on consumer insight and data analysis and driven by Novozymes’s strategic mission of “Rethink Tomorrow”.

     

    About Hongkong Winhealth Pharma Group Co., Ltd.

     

    Winhealth Pharma is an innovative biopharmaceutical company aiming at fulfilling unmet or underserved medical needs for patients and specializing in the commercial development and operation of drugs for rare diseases and specialized diseases and other clinical drugs in the Chinese and neighboring markets. Since its inception, Winhealth has been committed to sourcing, developing, and commercializing innovative therapies from leading biotech and pharmaceutical companies worldwide. Winhealth has established long-term strategic partnerships with a variety of leading firms including Roche, Pfizer, Kyowa Kirin, SHIONOGI, and Cumberland Pharmaceuticals and successfully built a diversified pipeline consisting of both clinical-stage and commercial-stage products. More information is available at http://www.winhealth.hkor WeChat Official Account of “Winhealth Pharma”.


    References:

    1. IHME, Global Burden of Disase, WHO.

    2. Whorwell P J , Altringer L , Morel J . Efficacy of an encapsulated probiotic Bifidobacterium infantis[J]. The American Journal of Gastroenterology, 2006, 101:326-333.

    3. Williams M D , Ha C Y , Ciorba M A . Probiotics as therapy in gastroenterology: a study of physician opinions and recommendations.[J]. Journal of Clinical Gastroenterology, 2010, 44(9):631-636.

    4. Liam O’Mahony, Mccarthy J , Kelly P , et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles.[J]. Gastroenterology, 2005, 128(3):541-551.


    3rd Floor, Winhealth Industrial Park, No. 272 Huancheng East Road, Xiacheng District, Hangzhou, Zhejiang, China
    BD@winhealth.Hk (overseas)
    0571-8718 6358    4008393773 ( Product Hotline )
    Copyright ©2019 - 2024 Zhejiang Medical Technology Development Co., Ltd.